Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Expert Review of Anticancer Therapy|April 18, 2020
EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapyPauline Hulo, Dahna Coupez, Marc G Denis, et al.Expert Opinion on Biological Therapy|January 19, 2020
Pembrolizumab for the treatment of colorectal cancerDahna Coupez, Pauline Hulo, Yann Touchefeu, et al.Expert Opinion on Biological Therapy|August 11, 2021
KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicineDahna Coupez, Pauline Hulo, Yann Touchefeu, et al.Current Oncology (Toronto, Ont.)|August 26, 2021
Carcinoembryonic Antigen Increase in a Patient with Colon Cancer Who Have Achieved Complete Remission and Negative 18F-FDG PET/CT: Don't Forget the Thyroid!Alexandre Lugat, Pauline Hulo, Catherine Ansquer, et al.Bulletin Du Cancer|March 14, 2024
[National survey of Advanced Practice Nurses in oncology-haematology: Evaluation of activity and continuing education]Elvire Pons-Tostivint, Laure De Decker, Gaëlle Haudebert, et al.Journal of Digestive Diseases|October 30, 2015
Predictive factors of splanchnic vein thrombosis in acute pancreatitis: A 6-year single-center experienceLaurence Toqué, Antoine Hamy, Jean-Francois Hamel, et al.Bulletin Du Cancer|March 12, 2026
[Evaluation of the return-to-work rate in systemically treated non-small cell lung cancer patient]Marie Cap, Virginie Nael, Loan Mouézy, et al.Respiratory Research|April 5, 2024
Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapyPauline Hulo, Sophie Deshayes, Judith Fresquet, et al.Clinical Lung Cancer|January 16, 2026
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on OsimertinibPascale Tomasini, Oscar Juan-Vidal, Raffaele Califano, et al.Pageof 1